Journal
JOURNAL OF TRADITIONAL AND COMPLEMENTARY MEDICINE
Volume 12, Issue 1, Pages 69-72Publisher
ELSEVIER
DOI: 10.1016/j.jtcme.2021.09.005
Keywords
SARS-CoV-2; Furin; COVID-19; Honokiol; Spike protein
Categories
Funding
- JSPS KAKENHI [JP20H00259, JP21K15283]
Ask authors/readers for more resources
This study found that honokiol has a remarkable inhibitory effect on SARS-CoV-2 infection, suggesting that honokiol and related traditional Chinese medicine may be potential therapeutic agents for treating SARS-CoV-2.
The coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has emerged as a pandemic and has caused damage to the lives of the people and economy of countries. However, the therapeutic reagents against SARS-CoV-2 remain unclear. The spike (S) protein of SARS-CoV-2 contains a cleavage motif at the S1/S2 boundary, known to be cleaved by furin. As cleavage is essential for S protein activation and viral entry, furin was selected as the target compound. In this study, we examined the inhibitory effects of two lignans (honokiol and magnolol) on furin-like enzymatic activity using a fluorogenic substrate with whole-cell lysates. Of two compounds tested, honokiol partially inhibited furin-like enzymatic activity. We further examined the anti-SARS-CoV-2 activity of honokiol using VeroE6 cell line, which is stably expressing a transmembrane protease serine 2 (TMPRSS2). It was shown that honokiol exhibited remarkable inhibition of SARS-CoV-2 infection. Therefore, honokiol and crude drugs which contain honokiol such as Magnolia species have a potential therapeutic reagents for SARS-CoV-2. (c) 2021 Center for Food and Biomolecules, National Taiwan University. Production and hosting by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/ licenses/by-nc-nd/4.0/).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available